Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 52.83% from the company’s current price.

CLDX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $51.00 target price for the company. Wells Fargo & Company upped their price objective on Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, August 12th. Finally, Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Stock Down 0.7 %

Shares of Celldex Therapeutics stock traded down $0.32 on Monday, reaching $43.84. The company’s stock had a trading volume of 51,043 shares, compared to its average volume of 763,974. Celldex Therapeutics has a 52 week low of $22.11 and a 52 week high of $53.18. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -15.38 and a beta of 1.56. The firm’s fifty day simple moving average is $38.14 and its two-hundred day simple moving average is $38.87.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. As a group, research analysts predict that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System lifted its stake in shares of Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 325 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares during the period. Principal Financial Group Inc. grew its holdings in Celldex Therapeutics by 10.0% during the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock valued at $552,000 after buying an additional 1,194 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in Celldex Therapeutics by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 21,812 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 1,274 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.